Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3556050 in Healthy Subjects
NCT04156750Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ly3556050 in chronic pain, diabetic polyneuropathy (DPN), osteoarthritis (OA) and 1 more (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration. Started Nov 2019; status: completed.
02
Drugs
ly3556050
03
Conditions
chronic paindiabetic polyneuropathy (DPN)osteoarthritis (OA)chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT04156750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156750.